Covered recipient · General Payments record
JERRY BAGEL
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$241,037.80
278 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $158,178.00 | 72 |
| Consulting Fee | $52,162.50 | 17 |
| Honoraria | $25,600.00 | 9 |
| Food and Beverage | $3,379.60 | 151 |
| Travel and Lodging | $1,612.75 | 27 |
| Education | $104.95 | 2 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $62,265.12 | 55 |
| AbbVie Inc. | $55,094.11 | 56 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $29,169.49 | 25 |
| UCB, Inc. | $16,974.07 | 21 |
| Incyte Corporation | $15,097.59 | 10 |
| Janssen Scientific Affairs, LLC | $14,463.00 | 11 |
| GENZYME CORPORATION | $14,079.44 | 11 |
| Janssen Biotech, Inc. | $7,519.76 | 32 |
| UCB SA | $6,720.00 | 1 |
| LEO Pharma Inc. | $4,920.08 | 10 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $4,423.65 | 3 |
| Novartis Pharmaceuticals Corporation | $3,763.64 | 15 |
| Mindera Corp | $2,275.00 | 1 |
| Regeneron Healthcare Solutions, Inc. | $2,182.25 | 6 |
| E.R. Squibb & Sons, L.L.C. | $1,812.50 | 1 |
| Galderma Laboratories, L.P. | $84.90 | 6 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $80.50 | 6 |
| Kyowa Kirin, Inc. | $44.18 | 3 |
| Allergan, Inc. | $22.59 | 2 |
| ORGANOGENESIS INC. | $17.54 | 1 |
| EPI Health, LLC | $15.06 | 1 |
| VYNE Pharmaceuticals Inc. | $13.33 | 1 |
Page 3 of 6; records 101–150 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JERRY BAGEL
NPI 1992772156 · CMS profile ID 226194
Allopathic & Osteopathic Physicians / Dermatology
EAST WINDSOR, NJ
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 6; records 101–150 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1992772156?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JERRY BAGEL, NPI 1992772156, CMS profile ID 226194. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992772156?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). JERRY BAGEL, NPI 1992772156, CMS profile ID 226194. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992772156?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- JERRY BAGEL, NPI 1992772156, CMS profile ID 226194, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1992772156?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
278 matching records · $241,037.80 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 278.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| UCB, Inc. | $13.18 | 09/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807402235 | CMS |
| Janssen Biotech, Inc. | $14.66 | 09/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788901555 | CMS |
| Lilly USA, LLC | $168.00 | 09/02/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818566465 | CMS |
| Lilly USA, LLC | $24.00 | 09/02/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819150159 | CMS |
| UCB, Inc. | $10,620.00 | 08/30/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807472109 | CMS |
| Galderma Laboratories, L.P. | $11.63 | 08/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 855262397 | CMS |
| Lilly USA, LLC | $1,750.00 | 08/27/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818557381 | CMS |
| Lilly USA, LLC | $2,800.00 | 08/27/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818567513 | CMS |
| Janssen Biotech, Inc. | $13.46 | 08/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788901589 | CMS |
| Lilly USA, LLC | $1,400.00 | 08/26/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818566463 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $14.60 | 08/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851891607 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $44.80 | 08/25/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851891619 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $115.62 | 08/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851891625 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $4,400.00 | 08/25/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851891627 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,480.00 | 08/24/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763774346 | CMS |
| Lilly USA, LLC | $61.02 | 08/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819122786 | CMS |
| Novartis Pharmaceuticals Corporation | $14.70 | 08/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812596763 | CMS |
| Novartis Pharmaceuticals Corporation | $1,200.00 | 08/19/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812596807 | CMS |
| UCB, Inc. | $14.09 | 08/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807388537 | CMS |
| AbbVie Inc. | $14.34 | 08/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793957001 | CMS |
| Lilly USA, LLC | $1,400.00 | 08/13/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819173331 | CMS |
| UCB, Inc. | $81.22 | 08/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807412961 | CMS |
| Regeneron Healthcare Solutions, Inc. | $14.12 | 08/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809557093 | CMS |
| AbbVie Inc. | $4,900.00 | 08/10/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793956989 | CMS |
| AbbVie Inc. | $13.06 | 08/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793956993 | CMS |
| AbbVie Inc. | $1.39 | 08/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793956997 | CMS |
| Novartis Pharmaceuticals Corporation | $13.01 | 08/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812596811 | CMS |
| AbbVie Inc. | $25.78 | 08/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793956985 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $83.65 | 08/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763774344 | CMS |
| Janssen Biotech, Inc. | $93.33 | 08/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788901571 | CMS |
| UCB, Inc. | $122.98 | 08/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807451255 | CMS |
| Lilly USA, LLC | $14.83 | 08/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818577235 | CMS |
| Novartis Pharmaceuticals Corporation | $13.91 | 08/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812596761 | CMS |
| Galderma Laboratories, L.P. | $14.10 | 08/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 855262395 | CMS |
| Novartis Pharmaceuticals Corporation | $1,200.00 | 08/03/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812596805 | CMS |
| UCB, Inc. | $3.09 | 08/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807373621 | CMS |
| Janssen Biotech, Inc. | $12.75 | 07/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788901539 | CMS |
| LEO Pharma Inc. | $52.49 | 07/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842137775 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $14.63 | 07/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851891609 | CMS |
| EPI Health, LLC | $15.06 | 07/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 854622737 | CMS |
| Mindera Corp | $2,275.00 | 07/27/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 855500929 | CMS |
| Novartis Pharmaceuticals Corporation | $12.34 | 07/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812596817 | CMS |
| Allergan, Inc. | $11.30 | 07/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 792696919 | CMS |
| Janssen Biotech, Inc. | $13.89 | 07/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788901575 | CMS |
| Regeneron Healthcare Solutions, Inc. | $2,112.00 | 07/22/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809557091 | CMS |
| AbbVie Inc. | $14.95 | 07/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793956981 | CMS |
| UCB, Inc. | $14.57 | 07/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807370575 | CMS |
| Janssen Scientific Affairs, LLC | $1,013.00 | 07/19/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788901619 | CMS |
| Lilly USA, LLC | $2,800.00 | 07/19/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818567511 | CMS |
| Lilly USA, LLC | $1,750.00 | 07/19/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818577231 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $797,065.37 | 260 |
| PY2024 | Recipient | $26,977.86 | 2 |
| PY2024 | Principal investigator | $1,895,847.54 | 706 |
| PY2023 | Recipient | $392,196.81 | 12 |
| PY2023 | Principal investigator | $1,391,205.66 | 410 |
| PY2022 | Recipient | $11,071.33 | 11 |
| PY2022 | Principal investigator | $1,496,091.59 | 247 |
| PY2021 | Recipient | $58,182.05 | 19 |
| PY2021 | Principal investigator | $2,017,632.60 | 255 |
| PY2020 | Recipient | $163,342.55 | 13 |
| PY2020 | Principal investigator | $1,360,186.40 | 226 |
| PY2019 | Recipient | $290,883.58 | 21 |
| PY2019 | Principal investigator | $4,913,153.54 | 200 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
260 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,086.83 | 12/12/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289698 |
| Principal investigator 1 | Incyte Corporation | $6,209.10 | 12/08/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619135 |
| Principal investigator 1 | Incyte Corporation | $52.14 | 12/01/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619066 |
| Principal investigator 1 | Incyte Corporation | $21.33 | 12/01/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619078 |
| Principal investigator 1 | Incyte Corporation | $1.02 | 12/01/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619107 |
| Principal investigator 1 | Incyte Corporation | $18.96 | 12/01/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619119 |
| Principal investigator 1 | Incyte Corporation | $4.74 | 12/01/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619126 |
| Principal investigator 1 | Incyte Corporation | $7.11 | 12/01/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619144 |
| Principal investigator 1 | Incyte Corporation | $14.22 | 12/01/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619148 |
| Principal investigator 1 | Incyte Corporation | $14.22 | 12/01/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619153 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $19,109.07 | 12/01/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289007 |
| Principal investigator 1 | Incyte Corporation | $2,531.00 | 11/24/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619073 |
| Principal investigator 1 | Incyte Corporation | $1,050.10 | 11/24/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619111 |
| Principal investigator 1 | Incyte Corporation | $1,629.00 | 11/24/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619114 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 11/20/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184263791 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 11/20/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184263793 |
| Principal investigator 1 | Incyte Corporation | $1,158.30 | 11/12/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619069 |
| Principal investigator 1 | Incyte Corporation | $2,169.00 | 11/12/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619122 |
| Principal investigator 1 | Incyte Corporation | $4.24 | 11/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619081 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 11/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619085 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 11/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619089 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 11/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619093 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 11/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619096 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 11/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619100 |
| Principal investigator 1 | Incyte Corporation | $270.80 | 11/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619133 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 10/23/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184253194 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $15,000.00 | 10/22/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY DBA ECZEMA TREATMENT CENTER OF CENTRAL NEW JERSEY | PILOT STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF DUPILUMAB IN COMBINATION WITH NARROWBAND UVB (NUVB) PHOTOTHERAPY IN THE TREATMENT OF MODERATE-TO-SEVERE AD | No dispute reported | 06/30/2026 | 1184251568 |
| Principal investigator 1 | Incyte Corporation | $959.90 | 10/20/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619129 |
| Principal investigator 1 | Incyte Corporation | $2,531.00 | 10/20/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619163 |
| Principal investigator 1 | Incyte Corporation | $2,531.00 | 10/20/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619167 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $22,077.61 | 10/15/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286993 |
| Principal investigator 1 | ABBVIE INC. | $4,000.00 | 10/09/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202516371 |
| Principal investigator 1 | ABBVIE INC. | $2,932.10 | 10/09/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202516373 |
| Principal investigator 1 | Incyte Corporation | $1,187.80 | 10/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619139 |
| Principal investigator 1 | Incyte Corporation | $2,531.00 | 10/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619177 |
| Principal investigator 1 | Incyte Corporation | $3.18 | 10/01/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619103 |
| Principal investigator 1 | Incyte Corporation | $48.54 | 10/01/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619159 |
| Principal investigator 1 | Incyte Corporation | $68.70 | 10/01/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619172 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 09/25/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184243011 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 09/25/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184243013 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $27,413.35 | 09/23/2025 | Non-covered Recipient Entity Schweiger Dermatology And Allergy East Windsor | A Single Center Study to Evaluate the Effectiveness and Safety of Deucravacitinib in combination with Enstilar for Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1235993761 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,512.09 | 09/23/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285836 |
| Principal investigator 1 | Incyte Corporation | $7,500.00 | 09/22/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619027 |
| Principal investigator 1 | Incyte Corporation | $2,500.00 | 09/22/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619052 |
| Principal investigator 1 | Incyte Corporation | $1,350.00 | 09/10/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619015 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 09/04/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184235107 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 09/04/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184235109 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 09/04/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184235111 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 09/04/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184235113 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 09/04/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184235115 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 09/04/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184235117 |
| Principal investigator 1 | ABBVIE INC. | $702.30 | 09/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202507887 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $300.00 | 08/27/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223284635 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,787.00 | 08/25/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175433065 |
| Principal investigator 1 | Incyte Corporation | $1,821.40 | 08/20/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619012 |
| Principal investigator 1 | Incyte Corporation | $1,482.00 | 08/20/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619019 |
| Principal investigator 1 | Incyte Corporation | $1,601.00 | 08/20/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619056 |
| Principal investigator 1 | Incyte Corporation | $1,482.00 | 08/20/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619059 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,818.29 | 08/19/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223284371 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,338.26 | 08/13/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223284221 |
| Principal investigator 1 | ABBVIE INC. | $2,357.50 | 08/06/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202502863 |
| Principal investigator 1 | ABBVIE INC. | $2,106.90 | 08/05/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202501586 |
| Principal investigator 1 | Incyte Corporation | $270.80 | 08/04/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619045 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,500.00 | 08/04/2025 | Non-covered Recipient Entity Schweiger Derm and Allergy-East Windsor | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175244351 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,683.00 | 08/04/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175433001 |
| Principal investigator 1 | Incyte Corporation | $1,350.00 | 08/01/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619024 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,462.00 | 08/01/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175432971 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,368.79 | 08/01/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223283607 |
| Principal investigator 1 | ABBVIE INC. | $22,877.50 | 07/31/2025 | Non-covered Recipient Entity PSORIASIS TREATMENT CENTER OF CENTRAL NEW JERSEY | A Phase 1 Pharmacokinetic Study in Healthy Subjects to Evaluate the Relative Bioavailability of Risankizumab Following Subcutaneous Administration with On-Body Injector | No dispute reported | 06/30/2026 | 1202500588 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,947.00 | 07/28/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175433026 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 07/24/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184218491 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,928.16 | 07/24/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283082 |
| Principal investigator 1 | Incyte Corporation | $865.40 | 07/18/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619031 |
| Principal investigator 1 | Incyte Corporation | $1,601.00 | 07/18/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619036 |
| Principal investigator 1 | Incyte Corporation | $1,482.00 | 07/18/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619049 |
| Principal investigator 1 | Incyte Corporation | $1,601.00 | 07/18/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619064 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,427.00 | 07/10/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175433054 |
| Principal investigator 1 | Incyte Corporation | $1,952.10 | 07/09/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619040 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,505.23 | 07/09/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223282432 |
| Principal investigator 1 | ABBVIE INC. | $2,932.10 | 07/02/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202494231 |
| Principal investigator 1 | ABBVIE INC. | $5,350.28 | 07/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202494233 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,462.00 | 06/27/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175432981 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,616.00 | 06/26/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175433071 |
| Principal investigator 1 | Incyte Corporation | $1,482.00 | 06/25/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618881 |
| Principal investigator 1 | Incyte Corporation | $1,966.50 | 06/25/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618885 |
| Principal investigator 1 | Incyte Corporation | $417.00 | 06/25/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618889 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 06/19/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184209420 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 06/19/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184209422 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 06/19/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184209424 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 06/19/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184209426 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 06/19/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184209428 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 06/19/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184209430 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 06/19/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184209432 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 06/19/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184209434 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 06/19/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184209438 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 06/19/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184209440 |
| Principal investigator 1 | Incyte Corporation | $1,222.00 | 06/11/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618867 |
| Principal investigator 1 | Incyte Corporation | $1,280.00 | 06/11/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618901 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,427.00 | 06/09/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175433049 |
| Principal investigator 1 | ABBVIE INC. | $2,323.99 | 06/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202487535 |
| Principal investigator 1 | ABBVIE INC. | $1,530.40 | 06/03/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202487537 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 06/03/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240524250 |
| Principal investigator 1 | Incyte Corporation | $34.35 | 06/03/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240524255 |
| Principal investigator 1 | Incyte Corporation | $9.72 | 06/03/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240524260 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 06/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618918 |
| Principal investigator 1 | Incyte Corporation | $12.36 | 06/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618929 |
| Principal investigator 1 | Incyte Corporation | $27.81 | 06/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618941 |
| Principal investigator 1 | Incyte Corporation | $148.85 | 06/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618950 |
| Principal investigator 1 | Incyte Corporation | $6.36 | 06/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618955 |
| Principal investigator 1 | Incyte Corporation | $64.72 | 06/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618959 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 06/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618974 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 06/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618978 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 06/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618981 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,910.00 | 06/02/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223280576 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,000.00 | 05/30/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175433032 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $22,077.61 | 05/27/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223280338 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,388.00 | 05/26/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175433059 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,676.00 | 05/22/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175432995 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,616.00 | 05/22/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175433036 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 05/22/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184198415 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 05/22/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184198419 |
| Principal investigator 1 | Incyte Corporation | $1,482.00 | 05/21/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618847 |
| Principal investigator 1 | Incyte Corporation | $1,143.90 | 05/21/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618870 |
| Principal investigator 1 | Incyte Corporation | $417.00 | 05/21/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618874 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $16,373.83 | 05/16/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223279918 |
| Principal investigator 1 | ABBVIE INC. | $5,567.37 | 05/07/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202482419 |
| Principal investigator 1 | ABBVIE INC. | $2,611.00 | 05/07/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202482421 |
| Principal investigator 1 | Eli Lilly and Company | $14,993.00 | 05/07/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187889056 |
| Principal investigator 1 | Incyte Corporation | $1,350.00 | 05/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618878 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 05/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618897 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 05/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618904 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 05/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618912 |
| Principal investigator 1 | Incyte Corporation | $8.48 | 05/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618963 |
| Principal investigator 1 | Incyte Corporation | $1,333.80 | 05/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618966 |
| Principal investigator 1 | Incyte Corporation | $406.20 | 05/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618970 |
| Principal investigator 1 | Incyte Corporation | $7.29 | 05/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618985 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 05/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618990 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 05/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618994 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 05/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618996 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 05/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619001 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 05/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619004 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,797.00 | 04/28/2025 | Non-covered Recipient Entity Schweiger Derm and Allergy-East Windsor | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175244406 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $24,951.70 | 04/17/2025 | Non-covered Recipient Entity Schweiger Dermatology And Allergy East Windsor | A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP) | No dispute reported | 06/30/2026 | 1235993759 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $25,700.00 | 04/11/2025 | Non-covered Recipient Entity Schweiger Dermatology And Allergy East Windsor | A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis | No dispute reported | 06/30/2026 | 1235993757 |
| Principal investigator 1 | Eli Lilly and Company | $3,096.00 | 04/10/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187889054 |
| Principal investigator 1 | Incyte Corporation | $1,656.00 | 04/09/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618859 |
| Principal investigator 1 | Incyte Corporation | $1,034.40 | 04/09/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618863 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 04/09/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240619008 |
| Principal investigator 1 | ABBVIE INC. | $9,265.06 | 04/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202469982 |
| Principal investigator 1 | ABBVIE INC. | $10,455.75 | 04/03/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202469986 |
| Principal investigator 1 | Incyte Corporation | $2,396.00 | 04/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618843 |
| Principal investigator 1 | Incyte Corporation | $2,396.00 | 04/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618851 |
| Principal investigator 1 | Incyte Corporation | $961.70 | 04/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618855 |
| Principal investigator 1 | Incyte Corporation | $42.23 | 04/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618894 |
| Principal investigator 1 | Incyte Corporation | $74.04 | 04/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618909 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 04/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618921 |
| Principal investigator 1 | Incyte Corporation | $16.18 | 04/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618925 |
| Principal investigator 1 | Incyte Corporation | $74.04 | 04/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618933 |
| Principal investigator 1 | Incyte Corporation | $0.93 | 04/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618938 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 04/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618945 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,995.00 | 03/31/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175433014 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,462.00 | 03/27/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175432978 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,263.00 | 03/24/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175433007 |
| Principal investigator 1 | Eli Lilly and Company | $12,194.00 | 03/18/2025 | Non-covered Recipient Entity JERRY BAGEL MD LLC | AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB | No dispute reported | 06/30/2026 | 1187885224 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,431.00 | 03/14/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223276735 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 03/12/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618590 |
| Principal investigator 1 | Incyte Corporation | $1,200.00 | 03/12/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618594 |
| Principal investigator 1 | ABBVIE INC. | $7,251.71 | 03/07/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202459774 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $14,719.59 | 03/07/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223276141 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,995.00 | 03/06/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175432987 |
| Principal investigator 1 | ABBVIE INC. | $2,418.60 | 03/04/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202455586 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 03/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618711 |
| Principal investigator 1 | Incyte Corporation | $1,333.80 | 03/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618730 |
| Principal investigator 1 | Incyte Corporation | $10.60 | 03/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618733 |
| Principal investigator 1 | Incyte Corporation | $68.70 | 03/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618740 |
| Principal investigator 1 | Incyte Corporation | $64.72 | 03/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618744 |
| Principal investigator 1 | Incyte Corporation | $0.62 | 03/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618749 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 03/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618754 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 03/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618758 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 03/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618761 |
| Principal investigator 1 | Incyte Corporation | $14.58 | 03/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618766 |
| Principal investigator 1 | Incyte Corporation | $74.04 | 03/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618769 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 03/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618773 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 03/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618792 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 03/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618801 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 03/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618804 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 03/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618811 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 03/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618816 |
| Principal investigator 1 | Incyte Corporation | $148.85 | 03/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618823 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,797.00 | 03/03/2025 | Non-covered Recipient Entity Windsor Derm | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175244389 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,875.00 | 03/03/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175433078 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,462.00 | 03/03/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175433084 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $19,851.66 | 03/03/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223275877 |
| Principal investigator 1 | UCB SA | $880.00 | 02/27/2025 | Non-covered Recipient Entity THE PSORIASIS TREATMENT CENTER OF CENTRAL NEW JERSEY | A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa | No dispute reported | 06/30/2026 | 1246657582 |
| Principal investigator 1 | Eli Lilly and Company | $2,495.04 | 02/25/2025 | Non-covered Recipient Entity EMKEY ARTHRITIS AND OSTEOPOROSIS | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187880585 |
| Principal investigator 1 | Janssen Research & Development, LLC | $45.00 | 02/25/2025 | Non-covered Recipient Entity Schweiger Derm Group-East Windsor | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175244375 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 02/20/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184155086 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 02/20/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184155090 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 02/20/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184155092 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,402.83 | 02/14/2025 | Non-covered Recipient Entity Schweiger Dermatology And Allergy East Windsor | Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) | No dispute reported | 06/30/2026 | 1235993763 |
| Principal investigator 1 | ABBVIE INC. | $3,023.10 | 02/11/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202450504 |
| Principal investigator 1 | Incyte Corporation | $1,443.60 | 02/10/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618623 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,317.00 | 02/07/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175433042 |
| Principal investigator 1 | ABBVIE INC. | $4,442.51 | 02/06/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202449720 |
| Principal investigator 1 | Biofrontera Inc. | $67,250.00 | 01/31/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC PSORIASIS TREATMENT CENTER OF CENTRAL NEW JERSEY | A SINGLE CENTER, OBSERVATIONAL STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF CRYOTHERAPY IN COMBINATION WITH AMELUZ RED LIGHT PDT IN THE TREATMENT OF ACTINIC KERATOSES ON THE FULL FACE. | No dispute reported | 06/30/2026 | 1208907279 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,400.00 | 01/31/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175433020 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $22,680.49 | 01/31/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY DBA ECZEMA TREATMENT CENTER OF CENTRAL NEW JERSEY | PILOT STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF DUPILUMAB IN COMBINATION WITH NARROWBAND UVB (NUVB) PHOTOTHERAPY IN THE TREATMENT OF MODERATE-TO-SEVERE AD | No dispute reported | 06/30/2026 | 1184151258 |
| Principal investigator 1 | Incyte Corporation | $1,482.00 | 01/27/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618631 |
| Principal investigator 1 | Incyte Corporation | $1,482.00 | 01/27/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618635 |
| Principal investigator 1 | Incyte Corporation | $1,144.50 | 01/27/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618808 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,368.95 | 01/23/2025 | Non-covered Recipient Entity Schweiger Derm Group-East Windsor | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175244343 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 01/23/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184149458 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 01/23/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184149460 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 01/23/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184149462 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 01/23/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184149466 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 01/23/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184149468 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,429.90 | 01/22/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY PC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223274407 |
| Principal investigator 1 | Eli Lilly and Company | $61,422.00 | 01/21/2025 | Non-covered Recipient Entity JERRY BAGEL MD LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187885570 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,914.00 | 01/16/2025 | Non-covered Recipient Entity Windsor Derm | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175244360 |
| Principal investigator 1 | Incyte Corporation | $1,399.20 | 01/15/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618599 |
| Principal investigator 1 | Incyte Corporation | $2,389.00 | 01/15/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618601 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 01/15/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618606 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 01/15/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618611 |
| Principal investigator 1 | Incyte Corporation | $417.00 | 01/15/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618615 |
| Principal investigator 1 | Incyte Corporation | $1,644.00 | 01/15/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618619 |
| Principal investigator 1 | ABBVIE INC. | $3,037.50 | 01/02/2025 | Non-covered Recipient Entity SDG DERMATOLOGY PC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202436061 |
| Principal investigator 1 | Incyte Corporation | $259.70 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618627 |
| Principal investigator 1 | Incyte Corporation | $275.60 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618639 |
| Principal investigator 1 | Incyte Corporation | $233.20 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618643 |
| Principal investigator 1 | Incyte Corporation | $80.70 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618647 |
| Principal investigator 1 | Incyte Corporation | $222.60 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618651 |
| Principal investigator 1 | Incyte Corporation | $116.60 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618655 |
| Principal investigator 1 | Incyte Corporation | $100.70 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618659 |
| Principal investigator 1 | Incyte Corporation | $68.90 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618663 |
| Principal investigator 1 | Incyte Corporation | $95.40 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618667 |
| Principal investigator 1 | Incyte Corporation | $43.04 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618669 |
| Principal investigator 1 | Incyte Corporation | $43.04 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618672 |
| Principal investigator 1 | Incyte Corporation | $42.40 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618674 |
| Principal investigator 1 | Incyte Corporation | $32.28 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618677 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618681 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618687 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618690 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618694 |
| Principal investigator 1 | Incyte Corporation | $37.10 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618697 |
| Principal investigator 1 | Incyte Corporation | $14.58 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618702 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618706 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618714 |
| Principal investigator 1 | Incyte Corporation | $0.93 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618717 |
| Principal investigator 1 | Incyte Corporation | $74.04 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618723 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618726 |
| Principal investigator 1 | Incyte Corporation | $16.18 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618736 |
| Principal investigator 1 | Incyte Corporation | $63.60 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618777 |
| Principal investigator 1 | Incyte Corporation | $63.60 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618781 |
| Principal investigator 1 | Incyte Corporation | $22.90 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618784 |
| Principal investigator 1 | Incyte Corporation | $406.20 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618787 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618797 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618826 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618832 |
| Principal investigator 1 | Incyte Corporation | $95.40 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618837 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 01/02/2025 | Non-covered Recipient Entity WINDSOR DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240618840 |